mRNA delivery of a class 1/4 SARS-CoV-2 neutralizing antibody protects against diverse sarbecoviruses in a lethal mouse challenge model
Proceedings of the National Academy of Sciences · 16.06.2026 · 123 (24)
DOI: 10.1073/pnas.2536870123 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 08.06.2026. Verfasst von Ashwin N Skelly und 39 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19, Antibodies, Viral, Antibodies, Neutralizing. Die Arbeit nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID), Bill and Melinda Gates Foundation (GF), Gates Foundation.
Abstract (Originalsprache)
The unyielding antigenic drift of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as well as the threat of future zoonotic sarbecovirus spillovers, has prompted the search for broadly neutralizing antibodies (bNAbs) to inform rational therapeutic and vaccine design. Here, we isolated and characterized 20 receptor binding domain (RBD)-directed bNAb lineages from a serially sampled SARS-CoV-2 patient who was infected and vaccinated during the early months of the pandemic. Thirteen of these targeted the highly conserved, cryptic class 1/4 or class 4 RBD epitopes and had long (18 to 26 amino acid) heavy chain complementarity determining region 3 loops that utilized the IGHD3-22 gene segment. Five bNAbs potently neutralized all 18 viruses in a panel containing SARS-CoV-2 variants up to the recently emerged XBB.1.5 and JN.1 strains as well as diverse sarbecoviruses from other clades. Structural analyses of the Ab401 and Ab568 bNAbs complexed with RBD and Spike trimer, respectively, revealed recognition features in common with other class 1/4 bNAbs. Prophylactic administration of Ab401 as a recombinant protein afforded robust protection against infectious challenge with either SARS-CoV-2_WA1 or a related bat sarbecovirus with zoonotic potential. A similar level of protection was achieved when the heavy and light chains of Ab401 were delivered as lipid nanoparticle-encapsulated mRNAs. These data expand the arsenal of SARS-CoV-2 bNAbs for clinical development and identify mRNA-based antibody delivery as a promising platform for both pandemic preparedness and protection of immunocompromised patients against emerging sarbecovirus variants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
- Department of Microbiology, University of Pennsylvania, Philadelphia, PA 19104.
- Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125.
- Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT 06510.
- Department of Immunobiology, Yale School of Medicine, New Haven, CT 06510.
- School of Biological Sciences, University of Southampton, Southampton SO17 1BJ, United Kingdom.
ORCID-Profile: Ashwin N Skelly, Chengcheng Fan, Joel D Allen, Andrew J Connell, Weimin Liu, Yingying Li, Jonathan L Torres, Meng Yuan, Michael S Saag, Andrew B Ward, Ian A Wilson, Max Crispin, Craig B Wilen, Pamela J Bjorkman, Beatrice H Hahn
Förderung
- HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
- Bill and Melinda Gates Foundation (GF)
- Gates Foundation
- NIAID NIH HHS
Zitieren
APA
Skelly, A. N., Fan, C., Keeffe, J. R., Ökten, A. B., Gavor, E., Newby, M. L., Allen, J. D., Kreider, E. F., Ding, W., Osbaldeston, R. A., Park, Y., Connell, A. J., Lituchy, M. G., Bibollet-Ruche, F., Radford, K. M., P West, A., Peña-Hernández, M. A., Cruickshank, K., Liu, W., …, & Hahn, B. H. (2026). mRNA delivery of a class 1/4 SARS-CoV-2 neutralizing antibody protects against diverse sarbecoviruses in a lethal mouse challenge model. Proceedings of the National Academy of Sciences, 123(24). https://doi.org/10.1073/pnas.2536870123
Vancouver
Skelly AN, Fan C, Keeffe JR, Ökten AB, Gavor E, Newby ML, et al. mRNA delivery of a class 1/4 SARS-CoV-2 neutralizing antibody protects against diverse sarbecoviruses in a lethal mouse challenge model. Proceedings of the National Academy of Sciences. 2026;123(24). doi:10.1073/pnas.2536870123
BibTeX
@article{Skelly2026,
author = {Skelly, Ashwin N and Fan, Chengcheng and Keeffe, Jennifer R and Ökten, Arya B and Gavor, Edem and Newby, Maddy L and Allen, Joel D and Kreider, Edward F and Ding, Wenge and Osbaldeston, Rebecca A and Park, Younghoon and Connell, Andrew J and Lituchy, Melinda G and Bibollet-Ruche, Frederic and Radford, Katelyn M and P West, Anthony and Peña-Hernández, Mario A and Cruickshank, Kendra and Liu, Weimin and Li, Yingying and Albertus, Amie and McWilliams, Brieyanna and Russell, Ronnie M and Konrath, Kylie M and Torres, Jonathan L and Yuan, Meng and Gao, Hongmei and Montefiori, David C and Saag, Michael S and Goepfert, Paul A and Kulp, Daniel W and Ward, Andrew B and Wilson, Ian A and Shaw, George M and Andrabi, Raiees and Crispin, Max and Weissman, Drew and Wilen, Craig B and Bjorkman, Pamela J and Hahn, Beatrice H},
title = {mRNA delivery of a class 1/4 SARS-CoV-2 neutralizing antibody protects against diverse sarbecoviruses in a lethal mouse challenge model},
journal = {Proceedings of the National Academy of Sciences},
year = {2026},
volume = {123},
number = {24},
doi = {10.1073/pnas.2536870123}
}
EUVIMED